Research summary
Three contributions span heart-failure forecasting, cardiovascular risk-factor metrics, and secondary-prevention guidelines. A modelling study projects U.S. heart-failure prevalence and direct medical costs from 2012 to 2030 by adapting an American Heart Association methodology that holds prevalence constant by age, sex, and race/ethnicity while incorporating rising cost trajectories and technology effects [2]. The model avoids double-counting comorbid conditions and quantifies the expected impact of population ageing on heart-failure-related healthcare expenditures. A second paper, from the AHA Goals and Metrics Committee, defines the construct of "ideal cardiovascular health" using seven measurable behaviours and factors (smoking status, body mass index, physical activity, diet, total cholesterol, blood pressure, fasting glucose) and supplies the surveillance metrics adopted as the AHA 2020 Impact Goals [1]. The third paper updates the 2001 AHA/American College of Cardiology secondary-prevention consensus statement, synthesising trial evidence published since 2001 on aggressive risk-factor management in patients with established coronary, peripheral arterial, aortic, or carotid disease [3]. Recommendations cover lipid lowering, blood-pressure control, antiplatelet therapy, and lifestyle measures, with the stated rationale that comprehensive risk reduction improves survival, reduces recurrent events and revascularisation, and improves quality of life. The three abstracts together describe contributions to population-level cardiovascular metrics, projection modelling of disease burden, and clinical-guideline writing, rather than original trial design or mechanistic work. Methodological contributions consist of adapting actuarial-style projection methods to heart-failure cost modelling, defining composite population-health endpoints, and producing evidence-graded recommendations within multi-author writing committees.
Recent publications
- 2013 ACCF/AHA Guideline for the Management of Heart FailureDOI
- Defining and Setting National Goals for Cardiovascular Health Promotion and Disease ReductionDOI
- 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart FailureDOI
- 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive SummaryDOI
- 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of AmericaDOI
- Forecasting the Impact of Heart Failure in the United StatesDOI
- 2022 AHA/ACC/HFSA Guideline for the Management of Heart FailureDOI
- AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 UpdateDOI
- Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE)DOI
- 2013 ACCF/AHA Guideline for the Management of Heart FailureDOI
The lab page does not clearly state student acceptance status. Email the professor directly to confirm.
How to apply
Email Gregg C. Fonarow 6-12 months before your application deadline. Read several recent papers and reference specific work in your message. Use our how to email a Japanese professor guide for the proven email structure.
For applications via MEXT scholarship: see our MEXT 2027 complete guide and university-specific University Recommendation track.
External profiles
- ORCID: https://orcid.org/0000-0002-3192-8093
- OpenAlex: openalex.org
Profile compiled from public sources (Researchmap, OpenAlex, Keio University faculty directory). Last refreshed 2026-05. Report incorrect information.